Apimeds Pharmaceuticals US, Inc. Net Asset Momentum
Apimeds Pharmaceuticals US, Inc. net asset momentum. Apimeds Pharmaceuticals US, Inc. (APUS) recorded a net asset momentum of 11391.2% as of December 2025, with net assets of $153.35 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See APUS total equity for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of Apimeds Pharmaceuticals US, Inc. (2021–2025)
Net asset momentum of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025. This chart tracks Apimeds Pharmaceuticals US, Inc.'s year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +11391.2%, with net assets of $153.35 Million USD as of December 2025. Check Apimeds Pharmaceuticals US, Inc. tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Apimeds Pharmaceuticals US, Inc. Net Asset Momentum by Year (2021–2025)
Apimeds Pharmaceuticals US, Inc. net asset momentum by year from 2021 to 2025. The table below shows the complete annual net asset history for Apimeds Pharmaceuticals US, Inc. from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see Apimeds Pharmaceuticals US, Inc. market cap and net worth.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $153.35 Million | $164.18 Million | $10.84 Million | ▲ +11391.2% |
| 2024 | $-1.36 Million | $13.06K | $1.37 Million | ▼ -4361.3% |
| 2023 | $31.87K | $422.08K | $390.20K | ▲ +104.5% |
| 2022 | $-713.61K | $6.17K | $719.78K | ▼ -199.2% |
| 2021 | $-238.48K | $172.17K | $410.65K | — |